Icon (NASDAQ:ICLR) Updates FY 2026 Earnings Guidance

Icon (NASDAQ:ICLR) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 10.000-11.000 for the period, compared to the consensus earnings per share estimate of 11.330. The company issued revenue guidance of $7.9 billion-$8.2 billion, compared to the consensus revenue estimate of $7.9 billion.

Icon Price Performance

ICLR stock opened at $136.80 on Friday. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. Icon has a one year low of $66.57 and a one year high of $211.00. The firm has a market capitalization of $11.05 billion, a PE ratio of 22.21, a P/E/G ratio of 3.09 and a beta of 1.23. The firm has a 50-day moving average of $112.28 and a two-hundred day moving average of $141.50.

Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, May 27th. The medical research company reported $2.52 EPS for the quarter, missing analysts’ consensus estimates of $2.95 by ($0.43). Icon had a net margin of 7.40% and a return on equity of 10.58%. The firm had revenue of $2.11 billion for the quarter, compared to analysts’ expectations of $1.98 billion. During the same period in the prior year, the company posted $3.43 earnings per share. Icon’s quarterly revenue was up 2.5% compared to the same quarter last year. Icon has set its FY 2026 guidance at 10.000-11.000 EPS. On average, analysts forecast that Icon will post 11.53 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on ICLR shares. Zacks Research lowered shares of Icon from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 25th. Leerink Partners set a $145.00 price objective on shares of Icon in a research report on Thursday. JPMorgan Chase & Co. dropped their price objective on shares of Icon from $175.00 to $120.00 and set a “neutral” rating on the stock in a research note on Monday, May 18th. Weiss Ratings lowered shares of Icon from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, March 18th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and issued a $126.00 price objective on shares of Icon in a research note on Friday. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $151.20.

Hedge Funds Weigh In On Icon

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Transamerica Financial Advisors LLC raised its position in Icon by 72.3% during the fourth quarter. Transamerica Financial Advisors LLC now owns 770 shares of the medical research company’s stock valued at $140,000 after acquiring an additional 323 shares in the last quarter. Parallel Advisors LLC raised its position in Icon by 57.3% during the fourth quarter. Parallel Advisors LLC now owns 703 shares of the medical research company’s stock valued at $128,000 after acquiring an additional 256 shares in the last quarter. NewEdge Advisors LLC raised its position in Icon by 2,051.8% during the third quarter. NewEdge Advisors LLC now owns 1,205 shares of the medical research company’s stock valued at $211,000 after acquiring an additional 1,149 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new position in Icon during the third quarter valued at approximately $207,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Icon by 15.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,185 shares of the medical research company’s stock valued at $207,000 after acquiring an additional 163 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.